IMNM (Immunome) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


IMNM Immunome Inc IMNM
44 GF Score
Price $19.77
GF Value $2.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Immunome Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Immunome's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

IMNM vs CLDX, ELVN, VERA: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Immunome's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Immunome's Margin of Safety % (DCF FCF Based) falls into.


IMNM
44GF Score
Immunome Inc IMNM
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $19.77 is trading 878.7% above its estimated GF Value™ of $2.02. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $2.02 vs. price of $19.77 (878.7% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.77
Price
$2.02
GF Value